ProBio Opens Flagship U.S. Plasmid & Viral Vector Manufacturing Facility in Hopewell, New Jersey to Advance Cell and Gene Therapy
The celebration included an open house event featuring a guided site tour, ribbon-cutting ceremony, and a keynote address by Donavon Decker, the first person in the world to receive gene therapy for any form of muscular dystrophy in 1999. Decker shared his experience from that landmark trial at Ohio State University—led by Dr. Jerry Mendell—and spoke movingly about how state-of-the-art facilities like ProBio's Hopewell site help translate scientific advances into real patient outcomes.
The ribbon-cutting ceremony featured remarks from prominent leaders: Debbie Hart, CEO of BioNJ; Courtney Peters–Manning, Mayor of Hopewell Township; John Coelho of the New Jersey Economic Development Authority (NJEDA); Michael Vreeland, Site Head of ProBio Hopewell; Allen Guo, CEO of ProBio; and Frank Zhang, Founder of GenScript and Chairman of Legend Biotech.
Mayor Courtney Peters-Manning welcomed the company warmly, stating: 'Hopewell Township is a wonderful place to live and work, and we are thrilled to welcome ProBio to our community, where they will make cutting-edge, life-changing therapies, in addition to creating high-skilled jobs.'
John Coelho of NJEDA emphasized the strategic significance of the opening: 'The opening of ProBio, a state-of-the-art fully integrated end-to-end Contract Development and Manufacturing Organization, will be a significant enhancement to the cell and gene biologics development and biomanufacturing ecosystem, anchoring New Jersey as a leader in the field. The potential to support production for global clinical trial registrations and close proximity to leading precision medical centers will enable faster access of breakthrough medicines to patients.'
Built to meet the most rigorous GMP standards, the Hopewell site is equipped to support clinical-stage development, process-development and scale-up for cell and gene therapy programs. This capability solidifies New Jersey's position as a leader in biopharmaceutical manufacturing. During the open house, guests toured advanced GMP suites and production lines, and engaged with ProBio's scientific and operations teams as well as industry, academic, and government partners.
'This is not just a new facility. It is a beacon of hope for patients waiting for cures,' said Allen Guo, CEO of ProBio. 'Opening the Hopewell center is a milestone in ProBio's global expansion and underscores our mission to support biopharma innovators with high-quality, responsive manufacturing solutions.'
Bringing over 110 high-skilled jobs to New Jersey, ProBio's Hopewell facility continues to expand its capabilities. GMP AAV manufacturing is set to launch by Q3 2025, with GMP LVV services to follow in Q1 2026—enabling support for a broader range of therapeutic candidates from early proof-of-concept through clinical readiness, all within one integrated site.
Located in the heart of New Jersey's rapidly expanding innovation corridor, ProBio's Hopewell facility serves as the company's North American hub, designed to support and complement its broader operations across North America and Europe. This strategic investment aligns with efforts to strengthen transatlantic biomanufacturing capacity and resilience—positioning the site to meet growing demand for advanced therapeutic production across both continents.
For more information about ProBio and its full suite of development and manufacturing services, please visit www.probiocdmo.com.
ABOUT PROBIO ProBio is a global leader in advancing the development and manufacturing of next generation biologics and advanced therapies for the biotech and pharmaceutical industries. As a fully integrated end-to-end Contract Development and Manufacturing Organization (CDMO), ProBio partners with its clients to optimize drug development, accelerate time-to-market, and provide comprehensive life-cycle support.
Through a collaborative, risk-sharing approach, ProBio offers flexible licensing and co-development options for new therapeutics, enabling partners to effectively navigate the complexities of human disease with adaptable, cutting-edge therapeutic approaches.
To learn more about ProBio services, please visit https://www.probiocdmo.com/.
CUSTOMIZED CDMO SOLUTIONS. DEVELOPED FASTER. DELIVERED BETTER.
Media Contact:Alvin Jogasuria Head of Marketing, Americas and Europe[email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
2 days ago
- Malaysian Reserve
CleanSpace Continues Rapid Growth, Strengthening its Concept-to-Commercialization Model
DOYLESTOWN, Pa., Aug. 14, 2025 /PRNewswire/ — Continuing its rapid growth, CleanSpace has significantly enhanced its leadership team, expanded its CleanShield service footprint, and reinforced its 'Concept to Commercialization' assurance to clients across the life sciences, pharmaceutical, biotech, and advanced manufacturing sectors. Leadership Enhancements Fuel Strategic MomentumIn February 2025, CleanSpace promoted Nicholas Vermont to Chief Operating Officer (COO). With a strong track record in operational process optimization and estimating, Vermont is now overseeing company-wide operations to ensure scalability, efficiency, and precision in project delivery. Concurrently, Brian Bennett ascended to Executive Vice President (EVP), expanding his influence from VP of Sales to leading CleanSpace's commercial strategy and long-term market positioning. Expanding Turnkey Capabilities with CleanShieldIn April 2025, CleanSpace strengthened its full-service model by appointing Robert Griffith as Chief Strategy Officer and Mike Wieffering as Vice President of the CleanShield Division. Griffith, with over 30 years of experience in sterile pharmaceutical facility management and capital programs, is leading the strategic growth of CleanShield, the company's post-construction service division. Wieffering, bringing more than 40 years of expertise in pharma cleanroom and mechanical project delivery—including leadership roles at Johnson Controls—oversees operational execution, compliance, and service delivery. As part of this expansion, CleanSpace opened its Ferndale, Michigan office, now serving as the national headquarters for CleanShield services. This dedicated hub, featuring a client showroom and technical workshop space, enhances the company's ability to deliver commissioning, qualification, and validation (CQV), maintenance programs, emergency response, technical documentation, and workforce development—closing the critical gap between construction turnover and GMP operations, and enabling rapid service response on a national scale. Advancing Preconstruction ExcellenceTo fortify its early-phase project capabilities, CleanSpace appointed Julie Tareco as Vice President of Preconstruction in July 2025. With 28 years of experience spanning MEP systems, low-voltage infrastructure, commissioning, and operations, Julie will lead estimating, planning, scope development, value engineering, and project handoff—ensuring clarity and excellence from day one. Charting the Course ForwardThese strategic enhancements affirm CleanSpace's evolution into a fully integrated cleanroom partner—from initial concept through commercialization. With leadership aligned, national expansion underway, and service depth expanding, CleanSpace is primed for continued growth and deeper client partnerships. 'CleanSpace's growth is more than operational,' states President Glenn VandeGrift. 'It's about forging trusted, enduring partnerships. With our strengthened leadership team, deeper service offering, and expanded footprint, we're delivering not just facilities—but commercialization certainty.' About CleanSpaceCleanSpace is a national leader in turnkey modular cleanroom and critical environment solutions. With in-house design, engineering, manufacturing, construction, commissioning, and post-construction services through CleanShield, CleanSpace delivers compliant, operational-ready facilities optimized for speed, quality, and long-term performance. Media Contact:Stephanie Raab, Director of Marketingsraab@
The Sun
01-08-2025
- The Sun
Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland
HONG KONG SAR - Media OutReach Newswire - 1 August 2025 - Cushman & Wakefield, a leading global real estate services firm, today released its Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland report. It is based on in-depth interview surveys we conducted on professionals active in the life sciences sector on the Chinese mainland. The life sciences industry on the Chinese mainland is undergoing a transformative phase, driven by progressive policies, groundbreaking innovations, the emergence of influential life sciences companies, and strategic regional development. This report delves into the latest trends shaping the sector. Policy Landscape – National and Local Catalysts Reforms enacted in 2024-2025 have significantly accelerated sector development. Nationally, China relaxed restrictions on foreign investment in gene and cell therapy and allowed the establishment of wholly foreign-owned hospitals in key cities. Regulatory incentives – such as data protection and marketing exclusivity – have improved market access for innovative drugs. Locally, cities like Beijing, Shanghai, Shenzhen, Guangzhou, and Suzhou are rolling out targeted subsidies, fast-track approvals, and ecosystem-building programmes that directly benefit biotech development. Recent national policy initiatives on the Chinese mainland Industry Innovation and Company Growth Chinese life sciences companies are moving beyond generic drug manufacturing toward innovative therapies. Firms like Akeso, BeiGene, Gracell, and Legend Biotech are now global players, leading in CAR-T, bispecific antibodies, and AI-assisted R&D. These companies are not only commercialising cutting-edge treatments but also attracting international investment and licensing agreements, reinforcing the Chinese mainland's global relevance in life sciences. Real Estate Development and Regional Hubs Innovation hubs such as Suzhou BioBAY, Zhangjiang Hi-Tech Park (Shanghai), and the Bioisland Innovation Centre (Guangdong) are central to regional clustering. These hubs offer end-to-end support, including shared labs, venture capital access, GMP-compliant facilities, and proximity to academic and clinical networks. The rise of second-tier innovation cities like Chengdu and Ningbo further expands growth corridors. The 'R&D + Manufacturing + Service' ecosystem Source: Cushman & Wakefield Research Landlord Perspectives – Evolving Real Estate Models Real estate developers and landlords are adapting to sector-specific requirements through asset-light models, flexible leasing, and high-specification lab and production space. Tier-1 cities face saturation, but central and western regions exhibit healthy demand. Developers are incorporating advanced sustainability and compliance features to meet growing regulatory and ESG expectations, particularly in GMP and cleanroom environments. Digitalisation, environmental policies, and differentiated tenant strategies are shaping performance. Operators now focus on integrated ecosystems with platforms that link tenants to R&D services, policy benefits, and technology partners. Occupier Perspectives – Growth, Innovation, and Challenges Life sciences occupiers are navigating regulatory reform, rising compliance demands, and intensified market competition. Many are localising production and R&D, leveraging regional subsidies, and investing in AI-powered innovation platforms. Occupiers seek flexibility, proximity to talent and infrastructure, and co-located R&D and manufacturing to support accelerated innovation and operational agility. In real estate, demand is strongest for GMP-certified labs, modular production facilities, and shared innovation platforms. Occupiers emphasise location advantages, sustainability certifications (e.g., LEED, WELL), and integration into clusters that enable faster time-to-market. Tony Su, Managing Director, National Head of Industrial & Logistics Property Services, China, said, 'Life sciences business parks on the Chinese mainland demonstrated clear regional differentiation, highlighting opportunities for strategic positioning. While Tier-1 cities saw more moderate performance due to broader macroeconomic factors and abundant supply, core cities in central and western regions recorded healthy occupancy rates, underpinned by strong industrial clustering and increasingly sophisticated ecosystems – contributing to steady growth in asset value.' Johnathan Wei, President, Project & Occupier Services, China, said, 'Several interviewed life sciences companies on the Chinese mainland achieved revenue growth supported by innovative products and favourable policy tailwinds. While overall growth remained modest for many, a select group reported strong performance, highlighting opportunities for differentiation'. Andrew Chan, Managing Director, Head of Valuation & Advisory Services, Greater China, said,' Looking ahead to 2025 and beyond, growth opportunities lie in AI-driven drug discovery, personalised medicine, advanced therapeutics (CGT, RNA), and green-certified facilities. Government policies continue to support innovation through fast-track approvals, rare disease funding, and subsidies aligned with dual-carbon and ESG goals'. Shaun Brodie, Head of Research Content, Greater China, 'Life sciences real estate is shifting from generic parks to specialised, digitally enabled campuses with high compliance and flexibility. Investment strategies increasingly emphasise long-term partnerships, collaborative operating models, and digital infrastructure. Both landlords and occupiers express cautious optimism, with strategic differentiation and regional targeting seen as keys to unlocking future value'. Please click here to download the full report.
Malaysian Reserve
28-07-2025
- Malaysian Reserve
The Gross Law Firm Reminds Sarepta Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025
NEW YORK, July 28, 2025 /PRNewswire/ — The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT). Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: CLASS PERIOD: June 22, 2023 to June 24, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy's present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements. DEADLINE: August 25, 2025 Shareholders should not delay in registering for this class action. Register your information here: NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SRPT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 25, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: dg@ (646) 453-8903
